Drug intelligence / Profile preview

AKG-120

Development stage: Preclinical
Lead developer: Akagera Medicines
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Long-acting Injectable

Overview

AKG-120 is a preclinical-stage antibacterial drug candidate being developed by Akagera Medicines for the treatment of Methicillin-resistant *Staphylococcus aureus* (MRSA) infections, with a specific focus on Otitis Media and Infective Endocarditis. The drug is an oxazolidinone-class antibiotic that functions by inhibiting bacterial protein synthesis. AKG-120 is formulated using Akagera's proprietary liposomal nanoparticle (LNP) technology, which encapsulates a novel small molecule active ingredient to enhance drug delivery, stability, and therapeutic efficacy. This approach aims to improve the pharmacokinetic profile and targeted delivery of the oxazolidinone payload to the site of infection.

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on AKG-120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKG-120.

Explore the full profile